Search Results - CARDIOVASCULAR SYSTEM AND PHARMACOTHERAPEUTICS

Refine Results
  1. 1

    Endocannabinoid system in cardiovascular disorders - new pharmacotherapeutic opportunities by Pedro Cunha, Ana M Romão, Filipa Mascarenhas-Melo, Helena M Teixeira, Flávio Reis

    Published in Journal of Pharmacy and Bioallied Sciences (2011-01-01)
    Get full text
    Article


  2. 2

    Pharmacotherapeutics Applications and Chemistry of Chalcone Derivatives by Jagjit Singh Dhaliwal, Said Moshawih, Khang Wen Goh, Mei Jun Loy, Md. Sanower Hossain, Andi Hermansyah, Vijay Kotra, Nurolaini Kifli, Hui Poh Goh, Sachinjeet Kaur Sodhi Dhaliwal, Hayati Yassin, Long Chiau Ming

    Published in Molecules (2022-10-01)
    Get full text
    Article


  3. 3

    Impact of the Renin-Angiotensin System on the Pathogeny and Pharmacotherapeutics of Neurodegenerative Diseases by Walther Bild, Alexandru Vasincu, Răzvan-Nicolae Rusu, Daniela-Carmen Ababei, Aurelian Bogdan Stana, Gabriela Dumitrița Stanciu, Bogdan Savu, Veronica Bild

    Published in Biomolecules (2022-10-01)
    Get full text
    Article


  4. 4

    PHARMACOTHERAPEUTIC STRATEGIES FOR ENDOTHELIAL DYSFUNCTION CORRECTION WITH USE OF STATINES IN SYNDROME OF SYSTEMIC INFLAMMATORY RESPONSE by Tatiana Denisyuk

    Published in Research Results in Pharmacology (2017-12-01)
    Get full text
    Article


  5. 5

    Anticoronavirus and Immunomodulatory Phenolic Compounds: Opportunities and Pharmacotherapeutic Perspectives by Naiara Naiana Dejani, Hatem A. Elshabrawy, Carlos da Silva Maia Bezerra Filho, Damião Pergentino de Sousa

    Published in Biomolecules (2021-08-01)
    Get full text
    Article


  6. 6

    Evaluation of the pharmacotherapeutic follow-up effectiveness in patients with dyslipidemia in the secondary health care in the Brazilian Unified Health System (SUS) by Fernanda Luize Faria, Lucimary Afonso dos Santos, Mário Augusto Cray da Costa, Camilo Molino Guidone, Marco Antonio Costa

    Get full text
    Article


  7. 7

    Type 2 Diabetes at a Military Health Centre in Brazil: Clinical and Pharmacotherapeutic Profile by André Henrique Freitas de Braga e Bessa, Julieta Ueta, Vinícius Diniz Mayrink, Rinaldo Eduardo Machado de Oliveira

    Published in Clinical Diabetology (2024-03-01)
    “…Multimorbidity was 97.6%, in which systemic arterial hypertension (71.8%), lipid disorders (65.9%) and cardiovascular diseases (26.5%) were the main clinical conditions. …”
    Get full text
    Article


  8. 8

    Pharmacotherapeutic profile, polypharmacy and its associated factors in a cohort of people living with HIV in Brazil by Robson Pierre Nascimento da Silva, Luana M. S. Marins, Lusiele Guaraldo, Paula Mendes Luz, Sandra W. Cardoso, Ronaldo I. Moreira, Vanessa da Gama Oliveira, Valdilea G. Veloso, Beatriz Grinsztejn, Rita Estrela, Thiago S. Torres

    Published in AIDS Research and Therapy (2023-08-01)
    “…Most frequently prescribed concomitant medications were nervous system (64.8%), antiinfectives for systemic use (60.0%), alimentary tract and metabolism (45.9%), cardiovascular system (40.0%) and respiratory system (37.1%). …”
    Get full text
    Article


  9. 9

    Cost-effectiveness analysis of a pharmacotherapeutic empowerment strategy for patients with type 2 diabetes mellitus by Ana Carolina Oliveira Gonçalves, Maurílio de Souza Cazarim, Cristina Sanches, Leonardo Regis Leira Pereira, Ana Márcia Tomé Camargos, Jéssica Azevedo Aquino, Andre Oliveira Baldoni

    Published in BMJ Open Diabetes Research & Care (2019-05-01)
    “…Background The economic feasibility of pharmacotherapeutic empowerment of patients with type 2 diabetes mellitus (DM2) is still not well established.Objectives To evaluate the cost-effectiveness of an individual pharmacotherapeutic empowerment strategy (IPES) for patients with DM2.Methods This is a cost-effectiveness study nested in a non-randomized clinical trial with patients ≥18 years of age, of both genders, with low and moderate cardiovascular risks. …”
    Get full text
    Article


  10. 10

    Prevalence of polypharmacy and pharmacotherapy complexity in elderly people living with HIV in Spain. POINT study by Mercedes Gimeno-Gracia, Javier Sánchez-Rubio-Ferrández, María de las Aguas Robustillo-Cortés, Ramón Morillo-Verdugo

    Published in Farmacia Hospitalaria (2020-07-01)
    “…The median number of comorbidities was 3.5 (2.0-5.0), 52.7% of them being cardiovascular; 50.0% related to the central nervous system; 17.6% hepatic; and 8.1% consisting in chronic pulmonary disease. …”
    Get full text
    Article


  11. 11

    Post-Partum Depression Lactating Rat Model for Evaluating Ketamine’s Safety as a Pharmacotherapeutic Treatment: Roles in Cardiac and Urinary Function by André Rinaldi Fukushima, Pedro Enrique Navas-Suárez, Juliana Weckx Peña Muñoz, Esther Lopes Ricci, Luís Antônio Baffile Leoni, Érico C. Caperuto, Leandro Yanase, Jeferson Santana, Elias de França, Jan Carlo Morais O. Bertassoni Delorenzi, Alcides Felix Terrivel, Gláucio M. Ferreira, Mario Hiroyuki Hirata, Lorena de Paula Pantaleon, Julia Zacarelli-Magalhães, Gabriel Ramos de Abreu, Paula A. Faria Waziry, Maria Aparecida Nicoletti, Helenice de Souza Spinosa

    Get full text
    Article


  12. 12

    INNs granted with specific storage requirements in Bulgarian pharmacies. Part 1: Medicines acting on cardiovascular and nervous system by Evgeni Grigorov, Maya Radeva-Ilieva, Kaloyan D. Georgiev

    Published in Pharmacia (2023-08-01)
    Get full text
    Article


  13. 13

    An integrated method of management for children with cardiovascular pathology by M. A. Babaykina, O. B. Gordeeva, N. V. Fedorova, N. D. Vashakmadze, N. V. Zhurkova, O. Ya. Smirnova, L. S. Namazova-Baranova

    Published in Лечащий Врач (2021-07-01)
    Get full text
    Article


  14. 14

    Prevalence of adherence to cardiovascular drugs in outpatients with coronary artery disease by Maria M. CRUZEIRO, Ronara S. GROIA-VELOSO, Bianca M. DIAS, Adriano M. REIS

    “…Beta-blockers 98.1% (n = 130) and renin-angiotensin system agents 68.3% (n = 101) were the most commonly used cardiovascular drug classes. …”
    Get full text
    Article


  15. 15

    Categorical Analysis of Database Consistency in Reporting Drug–Drug Interactions for Cardiovascular Diseases by Liana Suciu, Sebastian Mihai Ardelean, Mihai Udrescu, Florina-Diana Goldiş, Daiana Hânda, Maria-Medana Tuică, Sabina-Oana Vasii, Lucreţia Udrescu

    Published in Pharmaceutics (2024-02-01)
    “…Our paper aims to analyze drug interactions in cardiovascular diseases by selecting drugs from pharmacotherapeutic subcategories of interest according to Level 2 of the Anatomical Therapeutic Chemical (ATC) classification system. …”
    Get full text
    Article


  16. 16

    Improving treatment intensification to reduce cardiovascular disease risk: a cluster randomized trial by Selby Joe V, Schmittdiel Julie A, Fireman Bruce, Jaffe Marc, Ransom Laura J, Dyer Wendy, Uratsu Connie S, Reed Mary E, Kerr Eve A, Hsu John

    Published in BMC Health Services Research (2012-07-01)
    “…<p>Abstract</p> <p>Background</p> <p>Blood pressure, lipid, and glycemic control are essential for reducing cardiovascular disease (CVD) risk. Many health care systems have successfully shifted aspects of chronic disease management, including population-based outreach programs designed to address CVD risk factor control, to non-physicians. …”
    Get full text
    Article


  17. 17

    Blood pressure targets, medication considerations and special concerns in elderly hypertension: Focus on atherosclerotic cardiovascular diseases, atrial fibrillation, heart failure... by Ru-Yin Hsu, Hao-Yun Lo, Chien-Hao Chen, Yee-Jen Wu, Ding-Cheng Chan, Chih-Cheng Wu, Tzung-Dau Wang, Hsien-Li Kao, Wen-Jung Sun, Yen-Hung Lin, Hung-Ju Lin

    Get full text
    Article


  18. 18

    Review of Intranasal Active Pharmaceutical Ingredient Delivery Systems by Ruslan Safarov, Olga Fedotova, Anastasia Uvarova, Mariia Gordienko, Natalia Menshutina

    Published in Pharmaceuticals (2024-09-01)
    “…This article provides a review of research on the development of nasal preparations for treating local nasal cavity diseases (in particular, for antibiotic delivery), systemic diseases (analgesics, drugs for cardiovascular diseases, antiviral and antiemetic drugs), CNS disorders (Alzheimer’s disease, Parkinson’s disease, epilepsy, schizophrenia, depression), and vaccine delivery. …”
    Get full text
    Article


  19. 19

    Conceptual model of pharmaceutical care for patients with coronary heart disease and comorbid conditions in Ukraine by Natalia Bilousova

    “…The rationale for involving pharmacists in multidisciplinary teams has been substantiated, as this will enhance the quality of personalised care, prevent potential medicines interactions considering their metabolic profiles, reduce the risk of adverse reactions and improve patient adherence to pharmacotherapy.Conclusion: The model of pharmaceutical care for patients with CHD and comorbid conditions takes into account the cardiovascular continuum and pharmacotherapy, which will lead to a decrease in disease progression, pharmacotherapeutic risks, reduce the burden on the healthcare system and guarantee the safety of medicines use. …”
    Get full text
    Article


  20. 20

    The molecular activity of cannabidiol in the regulation of Nrf2 system interacting with NF-κB pathway under oxidative stress by Sinemyiz Atalay Ekiner, Agnieszka Gęgotek, Elżbieta Skrzydlewska

    Published in Redox Biology (2022-11-01)
    “…., is one of the most studied compounds in pharmacotherapeutic approaches to treat oxidative stress-related diseases such as cardiovascular, metabolic, neurodegenerative, and neoplastic diseases. …”
    Get full text
    Article


Search Tools: